ReviewAngewandte Chemie (International ed. in English)2017
From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.
Review in Angewandte Chemie (International ed. in English), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 76 citations in OpenAlex.
- Polymer- and Lipid-Based Nanostructures for Wound Healing with Barrier-Resolved Design.Pharmaceutics · 2025Review
- Development of Tumor Microenvironment-Responsive Nanoparticles with Enhanced Tissue Penetration.Nanomaterials (Basel, Switzerland) · 2025Article
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Celebrating World Cancer Day: Innovative Biological Approaches to Cancer and their Alignment with Sustainable Development Goals (SDGs).Biological procedures online · 2025Article
- Recent advances in the redox-responsive drug delivery nanoplatforms: A chemical structure and physical property perspective.Materials science & engineering. C, Materials for biological applications · 2021Review
- Biocompatible Polymers Combined with Cyclodextrins: Fascinating Materials for Drug Delivery Applications.Molecules (Basel, Switzerland) · 2020Review
- Nanoengineered targeting strategy for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- Engineering the Architecture of Elastin-Like Polypeptides: From Unimers to Hierarchical Self-Assembly.Advanced therapeutics · 2020Article
- Highly stable semiconducting polymer nanoparticles for multi-responsive chemo/photothermal combined cancer therapy.Theranostics · 2020Article
- The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs.International journal of nanomedicine · 2020Review
- Preparation of β-CD-DPPE-Dox Nanomedicine and Its' Application as the Anticancer and Antitumor Drug.Scientific reports · 2019Article
- Polymer-drug conjugate therapeutics: advances, insights and prospects.Nature reviews. Drug discovery · 2019Review
- Mesoporous Silica Nanomaterials: Versatile Nanocarriers for Cancer Theranostics and Drug and Gene Delivery.Pharmaceutics · 2019Review
- Theranostic Nanosystems for Targeted Cancer Therapy.Nano today · 2018Article
- Multistage delivery of CDs-DOX/ICG-loaded liposome for highly penetration and effective chemo-photothermal combination therapy.Drug delivery · 2018Article
- A Platinum(II) Complex of Heptamethine Cyanine for Photoenhanced Cytotoxicity and Cellular Imaging in Near-IR Light.Angewandte Chemie (International ed. in English) · 2018Article
- Dually responsive mesoporous silica nanoparticles regulated by upper critical solution temperature polymers for intracellular drug delivery.Journal of materials chemistry. B · 2017Article
- Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The molecular complexity and heterogeneity of cancer has led to a persistent, and as yet unsolved, challenge to develop cures for this disease. The pharmaceutical industry focuses the bulk of its efforts on the development of new drugs, but an alternative approach is to improve the delivery of existing drugs with drug carriers that can manipulate when, where, and how a drug exerts its therapeutic effect. For the treatment of solid tumors, systemically delivered drug carriers face significant challenges that are imposed by the pathophysiological barriers that lie between their site of administration and their site of therapeutic action in the tumor. Furthermore, drug carriers face additional challenges in their translation from preclinical validation to clinical approval and adoption. Addressing this diverse network of challenges requires a systems engineering approach for the rational design of optimized carriers that have a realistic prospect for translation from the laboratory to the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.